Member News

Novartis delivery of child-friendly antimalarial hits the 100 million mark

One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced. Coartem® Dispersible is the product of the partnership between MMV and Novartis.

This is the first who prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for pediatric medicines. Young children in Africa are disproportionately affected by malaria, with 86% of malaria deaths occurring in children under the age of 5 years.

Share this news article

22 February 2012